Prime medicine reports full year 2024 financial results and provides business updates

-- on track to report initial data from phase 1/2 clinical trial of pm359 for p47 phox cgd in 2025 -- -- ind-enabling studies ongoing for pm577 for wilson's disease; expect to file ind and/or cta in 1h 2026 -- -- additional high-value programs advancing through preclinical development -- cambridge, mass., feb. 28, 2025 (globe newswire) -- prime medicine, inc. (nasdaq: prme), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended december 31, 2024 and provided a business update.
PRME Ratings Summary
PRME Quant Ranking